HIV-1 viral protein R compromises cellular immune function in vivo

被引:37
作者
Ayyavoo, V
Muthumani, K
Kudchodkar, S
Zhang, DH
Ramanathan, P
Dayes, NS
Kim, JJ
Sin, JI
Montaner, LJ
Weiner, DB
机构
[1] Univ Penn, Dept Pathol & Lab Med, Stellar Chance Labs 505, Philadelphia, PA 19104 USA
[2] Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA 15261 USA
[3] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA
关键词
antigen-presenting cell; antigen-specific immune response; HIV-1 viral protein R; T cell activation; T(h)1/T(h)2 cytokine; vaccination;
D O I
10.1093/intimm/14.1.13
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
HIV-1 viral protein R (Vpr) is a virion-associated gene product that profoundly affects T cell proliferation, induces apoptosis and can affect cytokine production in part through interfering with NF-kappaB-mediated transcription from host cells. Collectively, these effects support that Vpr could influence immune activation in vivo. However, this effect of Vpr has not been explored previously. Here we examined the effect of Vpr expression in an in vivo model system on the induction of antigen-specific immune responses using a DNA vaccine model. Vpr co-vaccination significantly altered the immune response to co-delivered antigen. Specifically, in the presence of Vpr, inflammation was markedly reduced compared to antigen alone. Vpr reduced antigen-specific CD8-mediated cytotoxic T lymphocyte activity and suppressed T(h)1 immune responses in vivo as evidenced by lower levels of IFN-gamma. In the presence of Vpr, there is a profound shift in isotype towards a T(h)2 response as determined by the IgG2a:IgG1 ratio. The data support that Vpr compromises antigen-specific immune responses and ultimately effector cell function, thus confirming a strong selective advantage to the virus at the expense of the host.
引用
收藏
页码:13 / 22
页数:10
相关论文
共 56 条
[1]  
Agadjanyan MG, 1999, J IMMUNOL, V162, P3417
[2]   A C-terminal domain of HIV-1-accessory protein Vpr is involved in penetration, mitochondrial dysfunction and apoptosis of human CD4(+) lymphocytes [J].
Arunagiri, C ;
Macreadie, I ;
Hewish, D ;
Azad, A .
APOPTOSIS, 1997, 2 (01) :69-76
[3]   Development of genetic vaccines for pathogenic genes: construction of attenuated vif DNA immunization cassettes [J].
Ayyavoo, V ;
Nagashunmugam, T ;
Boyer, J ;
Mahalingam, S ;
Fernandes, LS ;
Le, P ;
Lin, J ;
Nguyen, C ;
Chattargoon, M ;
Goedert, JJ ;
Friedman, H ;
Weiner, DB .
AIDS, 1997, 11 (12) :1433-1444
[4]   HIV-1 Vpr suppresses immune activation and apoptosis through regulation of nuclear factor kappa B [J].
Ayyavoo, V ;
Mahboubi, A ;
Mahalingam, S ;
Ramalingam, R ;
Kudchodkar, S ;
Williams, WV ;
Green, DR ;
Weiner, DB .
NATURE MEDICINE, 1997, 3 (10) :1117-1123
[5]   ANTISENSE PHOSPHOROTHIOATE OLIGODEOXYNUCLEOTIDES TARGETED TO THE VPR GENE INHIBIT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REPLICATION IN PRIMARY HUMAN MACROPHAGES [J].
BALOTTA, C ;
LUSSO, P ;
CROWLEY, R ;
GALLO, RC ;
FRANCHINI, G .
JOURNAL OF VIROLOGY, 1993, 67 (07) :4409-4414
[6]   VIRUS-SPECIFIC CD8+ CYTOTOXIC T-LYMPHOCYTE ACTIVITY ASSOCIATED WITH CONTROL OF VIREMIA IN PRIMARY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION [J].
BORROW, P ;
LEWICKI, H ;
HAHN, BH ;
SHAW, GM ;
OLDSTONE, MBA .
JOURNAL OF VIROLOGY, 1994, 68 (09) :6103-6110
[7]   Enhancement of cellular immune response in HIV-1 seropositive individuals: A DNA-based trial [J].
Boyer, JD ;
Chattergoon, MA ;
Ugen, KE ;
Shah, A ;
Bennett, M ;
Cohen, A ;
Nyland, S ;
Lacy, KE ;
Bagarazzi, ML ;
Higgins, TJ ;
Baine, Y ;
Ciccarelli, RB ;
Ginsberg, RS ;
MacGregor, RR ;
Weiner, DB .
CLINICAL IMMUNOLOGY, 1999, 90 (01) :100-107
[8]  
BRINCHMANN JE, 1990, J IMMUNOL, V144, P2961
[9]   In vivo migration and function of transferred HIV-1-specific cytotoxic T cells [J].
Brodie, SJ ;
Lewinsohn, DA ;
Patterson, BK ;
Jiyamapa, D ;
Krieger, J ;
Corey, L ;
Greenberg, PD ;
Riddell, SR .
NATURE MEDICINE, 1999, 5 (01) :34-41
[10]  
Calarota SA, 1999, J IMMUNOL, V163, P2330